Generics, OTC AND API Groups Object To Proposed US Tariffs On Goods From China
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
AAM, CHPA, SOCMA and BPTF agree that proposed 25% tariffs on pharmaceuticals and APIs from China is a bad idea, unless perhaps it’s just a negotiating ploy.